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Abstract 
The international randomized controlled TARGIT A (TARGeted Intraoperative radiotherapy) trial 
demonstrated non-inferiority between the technique of TARGIT (Intra-Operative RadioTherapy (IORT) with 
Intrabeam®) and whole-breast external beam radiotherapy (EBRT) as part of the treatment for women with 
early breast cancer. The aim of this sub-study was to see if the single high dose of IORT leads to impaired 
aesthetic outcome in a group of patients participating in the trial at a single site. 
Frontal digital photographs were taken of women and analyzed, blinded to treatment received, by BCCT.core 
software. This produced scores for various measures of color.  
29 women (16 EBRT, 13 IORT) between 49 to 79 years old had photographs taken at baseline (up to 2 days 
prior to surgery), and again at 12 months (median 364 days). At 12 months there was a significant difference 
in cEMDL (p=0.002, Wilcoxon Two-Sample test, 2-sided) and other measures, indicating more “redness” in 
the breasts of the women in the EBRT group compared with the IORT group. This difference persisted after 
adjusting for tumor size, body mass index and age (p=0.0198, multiple regression analysis). 
This study provides further evidence for the early beneficial effect of TARGIT on aesthetic outcome. 
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Short Title 
Aesthetic outcome after breast conserving surgery and intraoperative radiotherapy.  
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Introduction 
The surgical treatment of early breast cancer has moved from radical (mastectomy) to minimally invasive 
(breast conserving surgery), and the benefits of this approach are well established [1,2]. 
However, radiotherapy treatment continues to involve irradiation of the whole breast. Techniques of intra-
operative radiotherapy (IORT) deliver therapeutic irradiation to the tumor bed from within the breast after 
wide local excision. Data from the randomized controlled trial of targeted intraoperative radiotherapy 
(TARGIT) has confirmed that, in selected women with early breast cancer, the technique is safe and as 
effective as conventional external beam radiotherapy to the whole breast [3,4,5,6].  
Furthermore, improvements in survival of patients with breast cancer [7] mean that the aesthetic outcome 
has become an increasingly important consideration. External beam radiotherapy can cause significant 
differences in color such as erythema, hyperpigmentation of the breast, hypopigmentation of the nipple–
areola complex and telangiectasia [8], and radiotherapy-associated fibrosis can impact on symmetry by 
causing upward retraction of the inferior mammary sulcus and/or the nipple–areola complex [9].  
A variety of methods for determining aesthetic outcome have been developed, many based on the 
subjective, overall cosmetic score classifying outcome as excellent, good, fair and poor as described in 1979 
by Harris et al. [10]. Cardoso et al. [11,12] developed a software program based on this classification 
system. Breast Cancer Conservative Treatment cosmetic results (BCCT.core) combines objective measures 
of asymmetry, skin color and scar from digital photographs, resulting in an overall aesthetic score that is a 
reproducible, objective evaluation of breast cancer conservation treatment [13]. 
The aim of this study was to compare the aesthetic results of a single biologically effective dose of 
radiotherapy given using TARGIT, with standard whole breast external beam radiotherapy, and expands on 
work presented previously [14]. 
Materials and Methods 
Women from a single site (Medical University in Lublin, Poland) participating in the TARGIT trial were 
included in this study. Patients were randomized to receive either IORT by the Intrabeam® (Carl Zeiss, 
Germany) device or conventional external beam radiotherapy as per local protocol.  
IORT was given according to the TARGIT technique as described [3]. Briefly, an applicator of appropriate 
size was placed directly into the lumpectomy cavity and the entire dose of radiation therapy was delivered to 
the tumor bed in a single fraction at the time of surgery (20Gy at surface of the applicator equivalent to 5–6 
Gy at depth of 1 cm from surface of the applicator). Therefore radiotherapy was given to the tumor bed, while 
sparing the normal tissue away from the tumor from the effects of radiation.  
EBRT was given to the whole breast as 25 fractions of 2Gy each, plus 5 fractions of 2Gy each, for a total 
dose of 50Gy plus 10Gy boost to the tumor bed. 
This study was conducted in accordance with the Declaration of Helsinki (1964), and local Ethical Committee 
approvals were in place before commencement. Written informed consent was obtained by all patients prior 
to enrolment, after which digital photographs were taken at baseline (prior to surgery) and one year later. 
Frontal views of the unclothed torso (from neck to navel) were used for objective analysis by BCCT.core 
software (BCCT.core 2.0, INESC Porto, Portugal). To extract color features of each breast, a histogram 
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analysis was carried out followed by an evaluation of dissimilarity [11]. All photographs were processed by 
one operator (NM) blinded to treatment received.  
Data on tumor and patient characteristics, and treatments given, were obtained from hospital notes. 
SAS version 9.4 was used to calculate the summary statistics of the population, the comparison of treatment 
groups using the 2-sided Wilcoxon Two-Sample test, and multiple regression analysis. 
Results 
42 patients from this site were randomized into the TARGIT A Trial. Of these, 37 women gave consent to 
participate in this sub-study. Eight patients were excluded from analysis as they either (a) did not have a 
photograph taken at one year (six patients), or (b) received both IORT and EBRT (two patients). The study 
population therefore comprised 29 women (16 EBRT, 13 IORT; see Figure 1), median age 56 years (range 
49 to 79) who had photographs taken at baseline (up to 2 days prior to surgery), and again at 12 months 
(median 364 days). Patients’ demographics, tumor characteristics and adjuvant treatments are summarized 
in Table 1. 
For patients who received IORT, the most commonly used applicator sizes were 45 and 40mm (four patients 
each), followed by 35mm (three patients), 30 and 25mm (one patient each). Within the TARGIT A Trial, IORT 
could be given either pre-pathology (at the same time as the wide local excision) or post-pathology (in a 
subsequent procedure after histopathology review of the excised tumor) [4]. All patients in this study were in 
the pre-pathology cohort. 
All patients randomized to receive external beam radiotherapy had a complete course of treatment, with no 
gaps. Note that two patients were excluded from analysis as they had IORT followed by EBRT (without 
boost), which is part of the “risk adjusted” strategy of the TARGIT technique [6]. 
At 12 months there were significant differences in several of the measures of color (see Figure 2), indicating 
more “redness” in the treated breasts of the women in the EBRT group compared with the IORT group. This 
difference remained after adjusting for tumor size, body mass index and age (p=0.0198). There were no 
significant differences in overall classification or measures of symmetry between treatment groups. 
Discussion 
This objective evaluation complements our previous work [15] and indicates that aesthetic outcome one year 
after surgery in patients treated with IORT when given as a first procedure (pre-pathology) is significantly 
better than those treated with EBRT.  
A likely explanation for this finding is that as intraoperative radiotherapy is delivered from within the breast 
the negative effect of radiotherapy to the skin is minimized. This result is in line with findings of the TARGIT 
trial showing that radiation toxicity was more frequent in the EBRT group than in the TARGIT group [3]. 
An argument can be made that the color changes associated with EBRT are of little consequence to the 
patient [16]. However, another view is that the “redness” is a surrogate for effects of radiation on normal 
tissue, and there may be unseen yet potentially serious side effects on the lungs and heart using EBRT that 
are not found with IORT [17]. For example, it has been shown that compared to the entire dose of radiation 
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delivered by TARGIT, just one fraction of EBRT is associated with a significantly greater change in γ-H2AX 
foci number in peripheral blood lymphocytes (a marker of dose delivered to the heart and great vessels) [18]. 
Conclusions 
This objective assessment of aesthetic outcome in patients from a randomized trial demonstrates that 
“redness” is significantly greater after one year in patients receiving EBRT compared with those receiving 
IORT, and adds to the evidence of the beneficial outcomes of TARGIT.  
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